- Home
- NVS vs AZN Comparison
NVS vs AZN Comparison
Compare NVS & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVS
- AZN
- Stock Information
- Founded
- NVS 1895
- AZN 1992
- Country
- NVS Switzerland
- AZN United Kingdom
- Employees
- NVS N/A
- AZN N/A
- Industry
- NVS Biotechnology: Pharmaceutical Preparations
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- NVS Health Care
- AZN Health Care
- Exchange
- NVS Nasdaq
- AZN Nasdaq
- Market Cap
- NVS 230.5B
- AZN 205.5B
- IPO Year
- NVS 1991
- AZN 1993
- Fundamental
- Price
- NVS $115.75
- AZN $72.83
- Analyst Decision
- NVS Hold
- AZN Strong Buy
- Analyst Count
- NVS 6
- AZN 5
- Target Price
- NVS $123.67
- AZN $92.33
- AVG Volume (30 Days)
- NVS 1.7M
- AZN 5.0M
- Earning Date
- NVS 07-17-2025
- AZN 07-24-2025
- Dividend Yield
- NVS 3.45%
- AZN 2.12%
- EPS Growth
- NVS N/A
- AZN 22.71
- EPS
- NVS 6.38
- AZN 4.97
- Revenue
- NVS $53,222,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- NVS $7.22
- AZN $9.56
- Revenue Next Year
- NVS $1.94
- AZN $6.09
- P/E Ratio
- NVS $17.41
- AZN $28.82
- Revenue Growth
- NVS 11.50
- AZN 15.48
- 52 Week Low
- NVS $96.06
- AZN $61.24
- 52 Week High
- NVS $120.92
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- NVS 62.89
- AZN 61.90
- Support Level
- NVS $111.06
- AZN $69.97
- Resistance Level
- NVS $113.91
- AZN $71.41
- Average True Range (ATR)
- NVS 1.57
- AZN 1.22
- MACD
- NVS 0.45
- AZN 0.42
- Stochastic Oscillator
- NVS 98.99
- AZN 94.74
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.